Livforsakringsbolaget Skandia Omsesidigt cut its position in shares of Becton Dickinson and Co (NYSE:BDX) by 50.4% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,360 shares of the medical instruments supplier’s stock after selling 2,400 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt’s holdings in Becton Dickinson and were worth $616,000 as of its most recent SEC filing.
Other institutional investors have also recently made changes to their positions in the company. Acropolis Investment Management LLC purchased a new stake in Becton Dickinson and during the 3rd quarter valued at about $101,000. Almanack Investment Partners LLC. purchased a new stake in Becton Dickinson and during the 2nd quarter valued at about $105,000. Truvestments Capital LLC purchased a new stake in Becton Dickinson and during the 3rd quarter valued at about $105,000. Bartlett & Co. LLC boosted its holdings in Becton Dickinson and by 2,900.0% during the 2nd quarter. Bartlett & Co. LLC now owns 450 shares of the medical instruments supplier’s stock valued at $108,000 after acquiring an additional 435 shares during the period. Finally, Bridgeworth LLC purchased a new stake in Becton Dickinson and during the 2nd quarter valued at about $131,000. Hedge funds and other institutional investors own 92.57% of the company’s stock.
NYSE BDX opened at $228.50 on Tuesday. Becton Dickinson and Co has a fifty-two week low of $203.99 and a fifty-two week high of $265.87. The company has a debt-to-equity ratio of 0.95, a current ratio of 1.23 and a quick ratio of 0.81. The company has a market capitalization of $61.27 billion, a price-to-earnings ratio of 21.93, a price-to-earnings-growth ratio of 1.36 and a beta of 1.11.
Several brokerages recently weighed in on BDX. Barclays began coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price for the company. Morgan Stanley increased their target price on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Wells Fargo & Co increased their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup increased their target price on Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Finally, Royal Bank of Canada restated a “hold” rating and set a $248.00 target price on shares of Becton Dickinson and in a report on Friday, August 3rd. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Becton Dickinson and has an average rating of “Buy” and an average target price of $255.40.
Becton Dickinson and Profile
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: Google Finance Portfolio Tips and Tricks
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.